We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+18.29%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$1.87B
AUM Growth
+$330M
Cap. Flow
+$161M
Cap. Flow %
8.59%
Top 10 Hldgs %
73.27%
Holding
30
New
3
Increased
7
Reduced
1
Closed
4

Top Buys

Rank Stock Value
1
ARVN icon
Arvinas
ARVN
+$51.7M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$50.5M
3
TGTX icon
TG Therapeutics
TGTX
+$44.8M
4
ZGNX
Zogenix, Inc.
ZGNX
+$37.3M
5
PGNX
Progenics Pharmaceuticals Inc
PGNX
+$23.3M

Top Sells

Rank Stock Value
1
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$58M
2
CLSD
Clearside Biomedical
CLSD
+$16.3M
3
AVEO
AVEO Pharmaceuticals, Inc.
AVEO
+$11.4M
4
SPRO icon
Spero Therapeutics
SPRO
+$10.9M
5
GTHX
G1 Therapeutics, Inc. Common Stock
GTHX
+$1.74M

Sector Composition

Rank Sector Weight
1 Healthcare 93.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WVE icon
1
Wave Life Sciences
WVE
$1.12B
$376M 20.08%
7,512,049
– –
ASND icon
2
Ascendis Pharma A/S
ASND
$16.5B
$300M 16.06%
4,240,536
– –
SLDB icon
3
Solid Biosciences
SLDB
$792M
$127M 6.78%
179,296
– –
ECYT
4
DELISTED
Endocyte, Inc. Common Stock
ECYT
$110M 5.88%
6,196,143
+546,259
+10% +$9.38M
ZGNX
5
DELISTED
Zogenix, Inc.
ZGNX
$93.2M 4.98%
1,878,768
+733,500
+64% +$37.3M
MYOV
6
DELISTED
Myovant Sciences Ltd.
MYOV
$91.6M 4.9%
3,451,859
+621,404
+22% +$14.1M
BCRX icon
7
BioCryst Pharmaceuticals
BCRX
$2.42B
$70.5M 3.77%
9,234,692
+2,250,000
+32% +$15.1M
RARX
8
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$69.7M 3.73%
3,851,808
– –
IFRX icon
9
InflaRx
IFRX
$243M
$67.5M 3.61%
1,967,848
+700
+0% +$22.6K
IMMU
10
DELISTED
Immunomedics Inc
IMMU
$65M 3.47%
3,119,778
– –
DRNA
11
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$60M 3.21%
3,933,489
– –
RYTM icon
12
Rhythm Pharmaceuticals
RYTM
$7.31B
$56.9M 3.04%
1,950,332
+408,589
+27% +$12.9M
ARVN icon
13
Arvinas
ARVN
$530M
$52.9M 2.83%
+3,138,412
New +$51.7M
SAGE
14
DELISTED
Sage Therapeutics
SAGE
$49.6M 2.65%
350,933
– –
CRNX icon
15
Crinetics Pharmaceuticals
CRNX
$8.88B
$48.7M 2.61%
+1,701,017
New +$50.5M
TGTX icon
16
TG Therapeutics
TGTX
$8.19B
$45.9M 2.45%
8,198,337
+3,919,541
+92% +$44.8M
MNTA
17
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$41M 2.19%
1,558,357
-2,144,176
-58% -$58M
KALV
18
DELISTED
KalVista Pharmaceuticals
KALV
$31.9M 1.7%
1,441,070
– –
EIDX
19
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$21.6M 1.15%
2,162,671
– –
KALA icon
20
KALA BIO
KALA
$12.5M
$20.9M 1.12%
846
– –
PGNX
21
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$19M 1.02%
+3,030,303
New +$23.3M
SCPH
22
DELISTED
scPharmaceuticals
SCPH
$16.8M 0.9%
2,857,143
– –
APLS
23
DELISTED
Apellis Pharmaceuticals
APLS
$16M 0.86%
900,000
– –
IOVA icon
24
Iovance Biotherapeutics
IOVA
$2.04B
$12.6M 0.67%
1,121,153
– –
CBIO
25
Crescent Biopharma
CBIO
$546M
$3.65M 0.2%
2,535
– –
1
2

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q3 2018 Portfolio in Review

As of Q3 2018, RA Capital Management held 30 positions worth $1.87B, up 21% from $1.54B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

RA Capital Management deployed $161M of net new capital in Q3 2018, opening 3 new positions and adding to 7 existing holdings. Its largest new stake was Arvinas: 3,138,412 shares worth $52.9M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 92% a quarter earlier.

On the sell side, the largest reduction was Momenta Pharmaceuticals, Inc., an estimated $58M trimmed.

  • RA Capital Management's largest Q3 2018 buy was Arvinas: 3,138,412 shares worth $52.9M.
  • RA Capital Management added most to TG Therapeutics in Q3 2018, an estimated $44.8M increase.
  • RA Capital Management's biggest Q3 2018 reduction was Momenta Pharmaceuticals, Inc., cutting an estimated $58M.
  • RA Capital Management fully exited Clearside Biomedical in Q3 2018, selling an estimated $16.3M.
  • RA Capital Management's ten largest holdings make up 73% of its $1.87B portfolio in Q3 2018.
  • RA Capital Management opened 3 new positions and closed 4 in Q3 2018.
  • RA Capital Management's portfolio value rose 21% quarter-over-quarter to $1.87B.

Based on RA Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.